|

Sotorasib Clinical Trials

17 actively recruiting trials across 11 locations

Also known as: AMG 510, AMG-510, AMG510, LUMAKRAS ®, LUMYKRAS ® +3 more

Pipeline

Phase 1: 5Phase 2: 6Phase 3: 2Phase 1/2: 2

Top Sponsors

  • Amgen5
  • National Cancer Institute (NCI)3
  • Memorial Sloan Kettering Cancer Center2
  • Vividion Therapeutics, Inc.1
  • NYU Langone Health1

Indications

  • Cancer17
  • Lung Cancer9
  • Stage III Lung Cancer AJCC v82
  • Stage IV Lung Cancer AJCC v82
  • Metastatic Lung Non-Small Cell Carcinoma2

Other4 trials

Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy
Phase 2
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Phase 2
Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients

Birmingham, Alabama2 trials

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

University of Alabama at Birmingham Cancer Center

Phase 2
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

University of Alabama at Birmingham Cancer Center

Phase 2

Basking Ridge, New Jersey2 trials

A Study of Sotorasib in People With Brain Tumors

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

Phase 1
A Study of Sotorasib in People With Non-Small Cell Lung Cancer

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

Chandler, Arizona1 trial

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Ironwood Cancer and Research Centers Scottsdale

Phase 3

Bakersfield, California1 trial

AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

Comprehensive Blood and Cancer Center

Phase 1

Duarte, California1 trial

Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer

City of Hope Medical Center

Phase 1

Los Angeles, California1 trial

Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

University of Southern California

Phase 1/2

Santa Barbara, California1 trial

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Sansum Clinic

Phase 3

Tampa, Florida1 trial

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

Moffitt Cancer Center-International Plaza

Phase 1/2

Grand Rapids, Michigan1 trial

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

START Mid West

Phase 1

Garden City, New York1 trial

Ladarixin With Sotorasib in Advanced NSCLC

NYU Langone Health

Phase 1

Houston, Texas1 trial

A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

University of Texas MD Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.